138 related articles for article (PubMed ID: 26123645)
21. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
[TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].
Ren YL; Wang HY; Zhou XY; Shan BE; Yang WT; Shen L; Shi DR
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):367-71. PubMed ID: 20646447
[TBL] [Abstract][Full Text] [Related]
23. Early stage uterine serous carcinoma: management updates and genomic advances.
Fader AN; Santin AD; Gehrig PA
Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
[TBL] [Abstract][Full Text] [Related]
24. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
25. HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma.
Banet N; Shahi M; Batista D; Yonescu R; Tanner EJ; Fader AN; Cimino-Mathews A
Am J Surg Pathol; 2021 May; 45(5):708-715. PubMed ID: 33739786
[TBL] [Abstract][Full Text] [Related]
26. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
27. Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma.
Shih IeM; Wang TL
J Pathol; 2011 May; 224(1):1-4. PubMed ID: 21432855
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
29. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.
Bashir S; Jiang G; Joshi A; Miller C; Matrai C; Yemelyanova A; Caputo TA; Holcomb KM; Ellenson LH; Gupta D
Int J Gynecol Cancer; 2014 Sep; 24(7):1262-7. PubMed ID: 25078343
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
31. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Zhao S; Choi M; Overton JD; Bellone S; Roque DM; Cocco E; Guzzo F; English DP; Varughese J; Gasparrini S; Bortolomai I; Buza N; Hui P; Abu-Khalaf M; Ravaggi A; Bignotti E; Bandiera E; Romani C; Todeschini P; Tassi R; Zanotti L; Carrara L; Pecorelli S; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Stiegler AL; Mane S; Boggon TJ; Schlessinger J; Lifton RP; Santin AD
Proc Natl Acad Sci U S A; 2013 Feb; 110(8):2916-21. PubMed ID: 23359684
[TBL] [Abstract][Full Text] [Related]
32. p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy.
Attias-Geva Z; Bentov I; Kidron D; Amichay K; Sarfstein R; Fishman A; Bruchim I; Werner H
Eur J Cancer; 2012 Jul; 48(10):1570-80. PubMed ID: 22033326
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
Dainty LA; Risinger JI; Morrison C; Chandramouli GV; Bidus MA; Zahn C; Rose GS; Fowler J; Berchuck A; Maxwell GL
Gynecol Oncol; 2007 Jun; 105(3):563-70. PubMed ID: 17400285
[TBL] [Abstract][Full Text] [Related]
34. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
35. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
36. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.
Bischof K; Knappskog S; Stefansson I; McCormack EM; Trovik J; Werner HMJ; Woie K; Gjertsen BT; Bjorge L
BMC Cancer; 2018 Jun; 18(1):684. PubMed ID: 29940909
[TBL] [Abstract][Full Text] [Related]
37. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Schwab CL; English DP; Roque DM; Bellone S; Lopez S; Cocco E; Nicoletti R; Rutherford TJ; Schwartz PE; Santin AD
Gynecol Oncol; 2014 Oct; 135(1):142-8. PubMed ID: 25124161
[TBL] [Abstract][Full Text] [Related]
38. Targeted therapy in the treatment of uterine serous carcinoma.
Schwab CL; Santin AD
Pharmacogenomics; 2015 Jan; 16(2):97-9. PubMed ID: 25616096
[No Abstract] [Full Text] [Related]
39. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
40. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas.
Reis H; Herold T; Ting S; Worm K; Huber U; Christoph DC; Eberhardt WE; Kostbade K; Kasper S; Stamatis G; Welter S; Darwiche K; Karpf-Wissel R; Theegarten D; Schmid KW; Schuler M; Wiesweg M
Lung Cancer; 2015 Apr; 88(1):34-41. PubMed ID: 25708529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]